SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy

Authors:

Abstract
Owing to its endogenous origin, well-defined nanocage architecture, and intrinsic affinity for transferrin receptor 1 (TfR1), human heavy-chain ferritin (HFn) has emerged as a promising platform for brain tumor drug delivery. However, the broad expression of TfR1 in normal tissues fundamentally limits tumor selectivity and therapeutic precision. Herein, we report a genetically engineered ferritin-based nanoplatform that achieves hierarchical dual-receptor targeting to address this challenge. By integrating the SpyCatcher/SpyTag conjugation system, ferritin nanocages were covalently and site-specifically functionalized with an epidermal growth factor receptor (EGFR) affibody, yielding FTn-EGFRAfb nanoparticles capable of coordinating TfR1-mediated transport with EGFR-driven tumor cell uptake. This modular engineering strategy preserves the native ferritin architecture and colloidal stability while enabling precise and irreversible ligand conjugation. Doxorubicin was efficiently encapsulated via a temperature-controlled loading approach, affording DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and excellent stability. In vitro studies demonstrated significantly enhanced cellular uptake and cytotoxicity toward EGFR-positive U87 glioma cells compared with non-targeted ferritin formulations. In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb markedly inhibited tumor progression and prolonged survival without evident systemic toxicity. Collectively, this work establishes a modular protein-engineering strategy that enables hierarchical TfR1/EGFR dual targeting while preserving the native architecture and transport advantages of ferritin nanocages. This platform provides a versatile framework for precision drug delivery in glioblastoma and other brain tumor therapies.